Simon and Shelley had a very productive meeting with the NHS Digital team last week who lead on data gathering and analysis. This forms a key part of …
Where’s my chair?
Action Duchenne’s Where’s my chair? campaign set out to achieve full wheelchair access for people living with Duchenne. We had a fantastic …
Information about Translarna MAA
We’re working with Muscular Dystrophy UK to make sure that emerging treatments for Duchenne get to those who need them, as quickly as possible. Since …
Wave gives suvodirsen update
Wave Life Sciences announced earlier this week that Suvodirsen has been granted fast track approval by the Federal Drug Administration (the drug …
Statement from the Board of Trustees
Action Duchenne does not routinely reply directly to comments on social media. However, given the understandable interest of the community following a …
Duchenne Standards of Care: Psychosocial
At the Action Duchenne International Conference in 2018, experts from across the world gave talks on topics around the current Standards of Care for …
Duchenne Standards of Care: Transition
At the Action Duchenne International Conference in 2018, experts from across the world gave talks on topics around the current Standards of Care for …
World Duchenne Awareness Day
Our Patron, Harry Hill and Ambassador, Jonny Gould share their messages on World Duchenne Awareness Day. …
Highlighting the importance of treatments for all
We recently wrote to the Medicines and Healthcare Products Regulatory Agency (MHRA) - the UK drug regulator - to highlight the importance of …
Vamorolone trial results published
Earlier this week the results of an early trial of vamorolone in boys with Duchenne have been published in the Neurology scientific journal. …
Ignite DMD update
In a press release yesterday, Solid Biosciences gave a short update on their gene therapy trial called Ignite DMD. Following the decision earlier this …
Sarepta issues clinical trials update
In recent press releases, Sarepta Therapeutics has given updates on their ongoing clinical trial programmes. These include exon skipping and gene …
